Latest Earnings Results: Q2 '26
Estimated EPS
-$3.73
Reported EPS
-$3.75
Surprise
-0.67%
Estimated Rev
$170.71M
Reported Rev
$122.33M
Surprise
-28.34%
• Reported GAAP EPS of -$3.24 down -102.50% YoY • Reported revenue of $145.8M down -44.10% YoY • BioNTech is revising its full-year 2026 revenue guidance to 1.61.9 billion, while maintaining adjusted SG&A expenses at 700800 million and adjusting R&D expense guidance to 2.02.3 billion for BioNTech.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q3 '26 | $0.86 | -- | -- | N/A |
Q2 '26 | -$3.73 | -$3.75 | -0.67% | MISSED |
Q1 '26 | -$2.57 | -$2.42 | 5.66% | BEAT |
Q4 '25 | -$0.19 | -$1.46 | -666.92% | MISSED |
Q3 '25 | -$1.11 | -$0.14 | 87.41% | BEAT |